February 2026
Thin Air Labs Founder Mindset Podcast with Catalina Vasquez
Click here for the Season 3 Episode 8 podcast
In this episode of The Founder Mindset, host Leah Sarich speaks with Catalina Vasquez, Co-Founder and COO of Nanostics […]
October 2025
Alberta Health Innovation Passport: ClarityDX Prostate reduces unnecessary biopsies and improves patient outcomes
HealthPro Canada Alberta Health Innovation Passport – Nanostics
Dr. Desmond Pink, Co-founder & CSO of Nanostics, speaking about Nanostics’ ClarityDX Prostate test. Click here to watch the YouTube video.
Category: Software as a Medical Device (SAMD) for early detection of prostate […]
Edmonton Global Trade Heroes Series – Nanostics’ ClarityDX Prostate early diagnostic test for aggressive prostate cancer
Nanostics Clinical Laboratory. Photo credit: Adam Becker, Intercept Photography
The “Trade Heroes” series highlights Edmonton region companies who have ‘EXPORT-itude‘ — By Amanda Sparks at
June 2025
Major Investment from Genome Canada to Help Advance ClarityDX Prostate Adoption Across Canada
Funding to Propel Widespread Adoption and Integration of Innovative Prostate Cancer Diagnostic Test into Canadian Healthcare
EDMONTON, AB, June 26, 2025 – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, announced today significant financial […]
April 2025
Nanostics Launches Clinical Utility Study for Its AI-Powered ClarityDX Prostate Test to More Accurately Identify Aggressive Prostate Cancer
- The first patient was enrolled this month in a Nanostics-sponsored clinical utility study in Calgary to quantify the impact of incorporating ClarityDX Prostate into the standard of care for the early detection of prostate cancer.
- The randomized two-arm control […]
Nanostics Receives CPSA Accreditation for its Newly Relocated Clinical Laboratory at the Biotechnology Business Development Centre in Edmonton
- Nanostics clinical lab relocates to Applied Pharmaceutical Innovation’s newly upgraded Biotechnology Business Development Centre in the Edmonton Research Park.
- Nanostics clinical lab has been granted provisional accreditation from the College of Physicians & Surgeons of Alberta (CPSA) to continue […]
February 2025
Nanostics and Protean BioDiagnostics Announce American Medical Association has Granted a PLA Code for ClarityDX Prostate
- ClarityDX Prostate is a validated blood-based diagnostic tool that uses AI-powered learning to help inform patients of their risk for aggressive prostate cancer.
- Florida-based Protean BioDiagnostics offers ClarityDX Prostate to healthcare providers and their patients suspected of having aggressive prostate […]
January 2025
Alan’s Story: Support in Prostate Cancer
Alan Budd’s journey with prostate cancer began unexpectedly, during a routine PSA test. For Alan, returning to the Cross Cancer Institute brought back memories of supporting his […]
November 2024
Tom’s Story: A Loss of Trust and The Importance of PSA Testing
This true story is being shared at the request of the deceased.
Tom Lucas retired as a captain with the Edmonton Fire Department after 30 years of service at the age of 54. He and his wife decided to retire to […]
Brad’s Journey: Advocacy and Support in Fighting Prostate Cancer
Brad:
“I had been getting my PSA (Prostate Specific Antigen) tested for a few years along with a DRE (digital rectal examine). In […]
Dr. John Lewis Speaks on “How can I protect myself from prostate cancer?” on CBC Podcast The Dose
Listen as Dr. John Lewis speaks on the CBC’s podcast The Dose by Dr. Brian Goldman: Prostate cancer is the most common cancer among Canadian men, with an estimated one in eight men expected to be diagnosed during their […]
October 2024
Sean Secord Speaks on Prostate Cancer Screening at PROSTAID
Sean Secord had the opportunity to speak at PROSTAID’s monthly meeting in Calgary, where he discussed the importance of prostate cancer screening and the impact ClarityDX Prostate can have on patients’ lives. The group was very […]
Nanostics Gets Featured on New Podcast by AIMSS
Nanostics was excited to be the first to be featured on a new podcast by AIMSS, called ByteMed! Watch us delve into the transformative world of diagnostic technology. Discover how the innovative platform, ClarityDX®, harnesses advanced machine learning algorithms […]
September 2024
Nanostics and OncoHelix Partner to Provide ClarityDX Prostate for Men at Risk of Having Aggressive Prostate Cancer in the Middle East
Business Wire
- OncoHelix will now offer the validated ClarityDX Prostate Risk Score to healthcare providers and their patients suspected of having aggressive prostate cancer.
- ClarityDX Prostate is a blood-based diagnostic tool that uses AI-powered learning to determine the risk […]
Nanostics and Protean Launch CDX Prostate for Men at Risk of Having Aggressive Prostate Cancer in the US
EDMONTON, Alberta–Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, and Protean Biodiagnostics Inc. (Protean) today announced their partnership to provide CDX Prostate in the United States.
CDX Prostate uses biological data, […]
Breakthrough test provides clarity for prostate cancer diagnosis
With support from the Canadian Cancer Society, Dr John Lewis took his research to new heights with an innovative test for prostate cancer screening.
“This test can tell you if you have a low or high risk of […]
July 2024
Nanostics Featured on Global News
Prostate cancer is one of the most common cancers among men in Canada, and early detection can save lives. Nicole Stillger from Global News talked with Nanostics COO Catalina Vasquez about how ClarityDX Prostate works and how […]
June 2024
Research supporting ClarityDX Prostate published in Nature Digital Medicine
Development of an effective predictive screening tool for prostate cancer using the ClarityDX machine learning platform
M. Eric Hyndman, Robert J. Paproski, Adam Kinnaird, Adrian Fairey, Leonard Marks, Christian […]
Nanostics Prostate Cancer Screening Test ClarityDX Prostate® accessible in British Columbia, Saskatchewan, and Ontario
EDMONTON, AB, June 5, 2024 /CNW/ – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, is thrilled to announce today that men can now provide blood samples for its […]
May 2024
Nanostics partners with CDL Laboratories to Provide Access to ClarityDX Prostate for Men at Risk of Having Aggressive Prostate Cancer
- Quebec-based CDL Laboratories will now offer the validated ClarityDX Prostate risk score to healthcare providers and their patients suspected of having aggressive prostate cancer.
- ClarityDX Prostate combines biological and clinical information using AI-powered learning to generate a risk score […]
Best Startup Workplace of the Year
Nanostics is thrilled to announce that we’ve been awarded Best Startup Workplace of the Year in the 2024 YEG Startup Community Awards! We extend heartfelt congratulations to all the nominees. We also express our gratitude to the YEG Startup […]
April 2024
Nanostics Receives Funding from the University of Alberta Innovation Fund to Propel Adoption of the ClarityDX Prostate Test
- University of Alberta Innovation Fund invests in Nanostics to support adoption of its ClarityDX Prostate test
- ClarityDX Prostate is a blood test that combines biological and clinical information using machine learning to generate a risk score for aggressive prostate […]
Prostate Cancer Screening in 2024
Dr. Chris Wallis talks about the benefits and harms of prostate cancer screening in 2024 using PSA and the addition of adjunctive tests like ClarityDX Prostate.
Video
Nanostics and Alberta Health Services collaborate to develop new diagnostic tools for urological diseases
- Nanostics and Alberta Health Services (AHS) agreement enables collaboration with AHS data scientists to develop new tools to improve the diagnosis of urological diseases.
- This collaboration will leverage Alberta’s comprehensive digital healthcare assets to improve patient care while satisfying […]
March 2024
January 2024
ClarityDX Prostate Breakthrough Prostate Cancer Test
ClarityDX Prostate is a breakthrough test that significantly advances prostate cancer screening. It provides critical support to men and their primary care providers in making more informed decisions, with […]
November 2023
ClarityDX Prostate: A New Way to Detect Prostate Cancer
On November 1, 2023, CEO John Lewis presented a webinar for
September 2023
Nanostics Launches ClarityDX Prostate Test in Alberta to Significantly Improve Prostate Cancer Screening
EDMONTON, ALBERTA – September 28 – Nanostics is thrilled to announce the availability of the ClarityDX Prostate test at its newly accredited clinical lab in Edmonton, Alberta. This innovative […]
Nanostics is Launching ClarityDX Prostate Test in Alberta on September 28
Join us in person to help celebrate this exciting event!
Launch Day! The official launch of our ClarityDX Prostate test in Alberta! Join us to hear from invited speakers and help celebrate this exciting milestone!
When: Thursday, September 28th – 4:00 […]
Nanostics Clinical Lab Granted Provisional CPSA Accreditation
CPSA https://cpsa.ca/facilities-clinics/accreditation/
- With this provisional accreditation from the College of Physicians and Surgeons of Alberta (CPSA), Nanostics clinical laboratory in Edmonton can now begin providing its ClarityDX Prostate test to patients.
EDMONTON, […]
June 2023
EV-Fingerprint test predicts aggressive prostate cancer
Clinical analysis of EV- Fingerprint to predict grade group 3 and above prostate cancer and avoid prostate biopsy
Adrian Fairey, Robert J. Paproski
Nanostics Announces New Medical Laboratory Director Todd McMullen
EDMONTON, AB, June 13, 2023 /CNW/ – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, announced today the appointment of Dr. Todd McMullen as the company’s new Medical Laboratory Director. In this role, Dr. McMullen […]
January 2023
Molecular Oncology: Building predictive disease models using extracellular vesicle microscale flow cytometry and machine learning
We developed the extracellular vesicle machine learning analysis platform (EVMAP) to improve the prediction of diseases such as cancer. The platform combines extracellular vesicle analysis using microscale cytometry with a machine learning approach to generate predictive models. In this work, […]
November 2022
Press Release: Nanostics Announces New Member of Board of Directors
Edmonton, Alberta – Nanostics Inc., a precision health diagnostics company, announced today the appointment of Aubrey Rankin to its Board of Directors. Mr. Rankin will join the board of directors at Nanostics replacing Mr. Reg Joseph as one […]
October 2022
News Release: Recognizing 10 years of philanthropic support for prostate cancer research
Two powerhouse researchers in prostate cancer will change the way we treat the disease, thanks to funding from legendary volunteer fundraisers, the Bird Dogs and the Alberta Cancer Foundation.
Working with the Alberta Cancer Foundation and the University […]
August 2022
Press Release: Nanostics Receives CE Mark for its ClarityDX Prostate® Test to Detect Clinically Significant Prostate Cancer
- Nanostics’ biomarker and machine learning-powered test, ClarityDX Prostate®, received a CE-IVD Mark.
- A CE-IVD Mark is required for all in vitro diagnostic (IVD) devices to be placed in the European Economic Area, Iceland, Norway, and Liechtenstein and allows Nanostics […]
July 2022
Press Release: Nanostics Announces the Launch of its Bladder Cancer Clinical Study Identifying Disease Predictors for Early Detection of Bladder Cancer
- Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America.
- The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder […]
June 2022
Press Release: Nanostics Announces Study Data Supporting ClarityDX Prostate as a Reflex Test to Predict Clinically Significant Prostate Cancer
Real-world data shows that at a 94% sensitivity level for prostate cancer ClarityDX Prostate® is 147% more specific than the PSA test for predicting clinically significant prostate cancer. Using ClarityDX Prostate® as a reflex test vs. PSA […]
Liquid biopsy EV analysis with small particle flow cytometry
Click here for CYTO 2022 POSTER PRESENTATION
Click here for CYTO 2022 SLIDE PRESENTATION
Small particle flow cytometry using 3 light scatter detectors enhances extracellular vesicle analysis in liquid biopsies, highlighting the potential to segregate EVs by refractive index
October 2021
Nanostics Welcomes New Board Member Mike Schoenberger
Nanostics is EXCITED to announce Mike Schoenberger as its newest Board Member! We also send a huge THANK YOU to outgoing board member Dale Klein for his dedicated service. Full Article
Antibody titration for flow cytometric analysis of Extracellular Vesicles: Are cell based protocols up to the task?
Date: 06/10/2021
Time: 10:00 am
Venue: Watch on Demand Now by clicking on the Address Button
Desmond Pink, CSO Nanostics
Why is ANTIBODY TITRATION critical to the success of any flow cytometry experiment?
In this webinar, Desmond Pink will investigate and report on antibody titration considerations for EVs, […]
October 2020
BMJ Open Cohort Profile Article: the Alberta Prostate Cancer Research Initiative (APCaRI) Registry and Biorepository facilitates technology translation to the clinic through the use of linked, longitudinal clinical and patient-reported data and biospecimens from men in Alberta, Canada
The APCaRI Registry and Biorepository, established in 2014, facilitates the collection of clinical and patient-reported data plus biospecimens, to measure prostate cancer outcomes and support the development and clinical translation of innovative technologies. The ultimate goal is to better diagnose […]
July 2020
White Paper: Performance Qualification for MicroFlow Cytometers: Understanding technical limitations to improve your research
As microflow cytometry matures toward clinical applications for extracellular vesicle (EV) analysis, a concerted effort to improve reproducibility has begun. The new MISEV and MISEV MISEV-Flow guidelines are critical to enabling this reproducibility.
AUTHOR: DESMOND PINK, MICHAEL WONG, DIANA […]
June 2020
Nanostics Re-Opens ClarityDX Prostate Clinical Study with New US Recruitment Site
PR: Nanostics announced the re-opening of their clinical validation study testing ClarityDX Prostate in a real-world setting. The study is also greatly benefiting from further expansion into the US with the addition of a new patient recruitment site at an […]
April 2020
Nanostics is Developing and Validating a Simple Blood Test to Predict Severity of COVID-19 Disease in SARS-CoV-2 Positive Patients
PR today: Nanostics to use ClarityDX platform to develop & validate a blood test to predict COVID-19 severity in SARS-CoV-2 patients; with Canadian BioSample Repository in Alberta and Century Clinical Research Institute in Florida. Full Article […]
January 2020
Alberta Impact with Bryce Lambert, Episode 3, ‘Future of Health’ DynaLIFE Accelerator Lab; benefits of this amazing Medical Lab program
Your technology’s proven in an academic lab⎯now you want it adopted into the healthcare system. The DynaLIFE Accelerator helps startups develop and validate tests in a real-world setting. Full Article
Validation of ClarityDX Prostate as a Reflex Test to Refine Prediction of Clinically Significant Prostate Cancer: ClinicalTrials.gov ID: NCT03957252
Clinical study to validate ClarityDX Prostate as a reflex test to high PSA levels to refine prediction of clinically significant prostate cancer has begun in a prospective cohort of 2800 men. Full Article
CBC News-Biotech firm recruiting Yukon men for trial, Prostate cancer group says it could save lives
Alberta-based Nanostics is hoping to recruit 200 Yukoners to the clinical validation study testing ClarityDX Prostate in a real-world setting. Full Article
CKRW 96.1 FM Radio-Cancer Study Comes to the Yukon
The Yukon Ride for Dad, which raises money for prostate cancer awareness and research, is making a substantial investment in Nanostic’s research into diagnostic testing for prostate cancer. Full Article
December 2019
Movember and Alberta Cancer Foundation campaigns boost prostate cancer screening study
News Medical Lifesciences – ClarityDX Prostate cancer diagnostic test validation study gets a boost in recruitment thanks to concurrent fundraising campaigns. Full Article
November 2019
Cowpea mosaic virus nanoparticles for cancer imaging and therapy
Nanoparticle platforms are attractive for theranostic applications due to their multifunctionality and multivalency. Some of the most promising nano-scale scaffolds have been co-opted from nature, such as the cowpea mosaic virus (CPMV). What makes CPMV so promising? They are non-infectious […]
October 2019
ClarityDX Prostate clinical validation study is expanding into the US with Century Clinical Research, Inc.
The Nanostics & APCaRI co-sponsored ClarityDX Prostate clinical validation study is expanding into the US by opening the Daytona Beach, Florida Century Clinical Research, Inc. recruitment site. Full Article
Nanostics featured on Alberta Impact Episode 5 with Bryce Lambert
1 of 7 Canadian men is diagnosed with prostate cancer each year. We cannot emphasize enough on how important it is to get tested each year. Nanostics has come up with a non-invasive diagnostic test to bring clarity to healthcare […]
September 2019
The Cancer Consortium-Nanostics: Advanced Machine Learning to Detect Prostate Cancer
Nanostics’ core technology, ClarityDX, combines a sensitive extracellular vesicle detection platform with advanced machine learning to diagnose a disease from a simple blood test. Full Article
June 2019
Prostate Cancer News Today: Nanostics Launches Pivotal Study to Validate ClarityDX Prostate Diagnostic Test.
Ana Pena wrote for the Prostate Cancer News Today: The company says the diagnostic tool has the potential to spare many men unnecessary biopsies and treatments. Full Article
Faculty of Medicine & Dentistry: U of A spin-off company Nanostics launches clinical validation study for ClarityDX Prostate
NEWS STAFF REPORT: Blood test predicts aggressive prostate cancer with greater accuracy and less patient discomfort. Full Article
May 2019
Nanostics and DynaLIFE productive partnership – video interview with Edmonton Journal
CSO Desmond Pink discusses Nanostics’ productive partnership with DynaLIFE Medical labs’ Translational Research Program- a key relationship to bring ClarityDX to market. Full Article
PROSPeCT: A Predictive Research Online System for Prostate Cancer Tasks
We are pleased to present PROSPeCT, a user-friendly online clinical information system that offers an efficient way to query APCaRIs (www.APCaRI.ca) robust and expanding patient database to generate relevant and accurate results. Read the details in our article published in […]
Nanostics develops better tests En Route magazine
Illustration by Martina Paukova
Full Article
January 2019
ClarityDX Prostate is one of five top picks for mind-blowing technologies and treatments in 2018
Global Edmonton Health reporter Su-Ling Goh highlighted 5 amazing medical technologies and treatments from Edmonton research teams and ClarityDX Prostate was one of them! Full Article
October 2018
Edmonton Journal – New lab brings fledgling health tech companies together in shared space
A local startup with plans to market a more accurate prostate cancer screening test is one of the first businesses to set up shop in a new downtown shared lab space for health tech companies. Full Article […]
Intravital imaging tumor screen used to identify novel metastasis-blocking therapeutic targets
This is a micro-review of an original research article from the Lewis research group that identified multiple novel metastasis-blocking targets, by using a whole genome screen and intravital imaging approach, that could be used as therapeutic targets to inhibit solid […]
September 2018
BioAlberta Recognizes Alberta Innovators and Entrepreneurs at 2018 Awards Gala
CALGARY, Alberta — At its 2018 awards gala, BioAlberta, the province’s life sciences industry association, recognized two leaders for their innovation and achievements. BioAlberta congratulates Circle Cardiovascular Imaging Inc. for winning its Company of the Year award and Dr. John […]
August 2018
FALLING WALLS
Dr. John Lewis is the winner of the University of Alberta-TEC Edmonton Falling Walls Venture Competition which earned him entrance to the Falling Walls Finale Competition (the International Conference on Future Breakthroughs in Science and Society) which will be held […]
July 2018
A Less Invasive Route to Test For Prostate Cancer
Alberta scientists, at Nanostics, have created a blood test that could make a significant impact in the way patients are tested and treated for prostate cancer. Full Article
May 2018
Funding to develop technology that will detect prostate cancer earlier
EDMONTON — Alberta Innovates, the Alberta Cancer Foundation and DynaLIFE have joined together to help commercialize Alberta-owned innovations that will detect cancer earlier and improve treatment for Albertans.
Full Article
September 2017
NVIDIA – How GPU-Powered Cellular Analysis Could Help Avoid Unnecessary Prostate Cancer Biopsies
1.3M North American men get biopsies each year checking for prostate cancer, many of them unnecessary. UofA researchers want to change that with a new test that relies on GPU computing. Full Article
June 2017
Startup Nanostics preparing launch of blood-based biomarker test for prostate cancer
A new diagnostic will allow men to bypass painful biopsies to test for aggressive prostate cancer. Full Article
New blood test uses nanotechnology to predict prostate cancer
A new diagnostic will allow men to bypass painful biopsies to test for aggressive prostate cancer. Full Article
U of A uses nanotechnology to develop new test for aggressive prostate cancer
Alberta men diagnosed with prostate cancer could soon have a better blood test to help determine if they can bypass a painful and invasive biopsy. Full Article
May 2017
Could there soon be a better way to protect against prostate cancer?
The PSA test for prostate cancer has been linked to unnecessary treatments and biopsies. That’s prompted researchers to start developing a more accurate prostate cancer detection tool. Full Article
